AXLRx (MoatRx Consulting)

TYPE 2 DIABETES — US Two IRA negotiation cycles have now cut across the T2D formulary: Januvia down 79% to $113, Jardiance down 66% to $197, Farxiga down 68% to $178 from January 2026, and semaglutide down 71% to $274 with Janumet and Tradjenta added for 2027. Type 2 diabetes has more IRA-negotiated agents on the books than any other therapy area, because CMS selected agents from this class in both of its first two negotiation cycles. IPAY 2026, effective January 1 2026, set Maximum Fair Prices of $113 a month for Januvia (sitagliptin) off a $527 list, a 79% cut; $197 for Jardiance (empagliflozin) off $573, a 66% cut; and $178 for Farxiga (dapagliflozin) off $556, a 68% cut. Those three cuts alone reset the DPP-4 and SGLT2 formulary tiers that most commercial plans had built around list-minus-rebate economics. IPAY 2027 widens the negotiated set again, and does so across drug classes rather than within one. Semaglutide's franchise (Ozempic, Rybelsus, Wegovy) is cut 71% to $274 for a 30-day supply off a roughly $959 list. Janumet (sitagliptin/metformin) and Tradjenta (linagliptin) join the negotiated list for the same cycle. A pricing strategy built only on the IPAY 2026 cohort is now incomplete; the negotiated share of the T2D formulary roughly doubles in scope from 2026 to 2027, and each new agent added changes which comparator a payer will reference when negotiating the agents CMS has not yet touched. ICER's 2019 assessment of oral semaglutide (Rybelsus) is the value-based anchor still in use for the DPP-4/SGLT2/GLP-1 comparison, and it is not a flat verdict. ICER found oral semaglutide met cost-effectiveness thresholds as an add-on to metformin, but rated it less cost-effective than empagliflozin in the same add-on-to-metformin position. That finding predates both negotiation cycles, and the two negotiated prices now sitting below ICER's threshold (Jardiance's $197 MFP, semaglutide's $274 MFP) change how that 2019 ranking should be read for a 2026-2027 formulary decision. IPAY 2026 already cut three T2D agents by 66-79%. IPAY 2027 adds semaglutide, Janumet, and Tradjenta to the same table, and each cycle changes the competitive net-price map differently. 3 questions this report answers: Q1 - How do the IPAY 2026 cuts to Januvia, Jardiance, and Farxiga change the net-price map across the DPP-4 and SGLT2 tiers? Q2 - What does IPAY 2027 adding semaglutide, Janumet, and Tradjenta do to the competitive set an un-negotiated agent has to price against? Q3 - Does ICER's 2019 cost-effectiveness ranking of oral semaglutide vs empagliflozin still hold once both agents carry a negotiated MFP? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #Type2Diabetes #US #PricingStrategy #AXLRx #PharmaMarketAccess Live report page: https://lnkd.in/dfQv4fqE

SPINAL MUSCULAR ATROPHY — UNITED STATES Zolgensma lists at $2.125 million, but ten state Medicaid programs now pay a $212,500 annual annuity instead. Onasemnogene abeparvovec lists at $2.125 million for a single infusion, the reference price every SMA access conversation starts from. But list price is not transaction price for a widening share of the market. Ten state Medicaid programs have enrolled in the Centers for Medicare and Medicaid Services' Cell and Gene Therapy Access model, which converts the one-time list price into a milestone-linked annuity of roughly $212,500 a year for ten years, contingent on the child sustaining motor-function gains under annual review. That structure, negotiated once and now replicated, is the actual price precedent the market has set, and it is the number any future SMA gene therapy will be priced against. The two chronic therapies price on an entirely different axis. Nusinersen costs roughly $750,000 in year one and about $375,000 a year in maintenance thereafter; risdiplam runs about $340,000 a year, weight-based, for life. Benefit routing compounds the comparison: nusinersen, physician-administered by intrathecal injection, routes to Medicare Part B with minimal patient cost-sharing for dual-eligible beneficiaries, while oral risdiplam routes to Part D, exposing patients to coinsurance that can exceed the intrathecal route's out-of-pocket cost. Over a ten-year horizon, cumulative chronic-therapy spend approaches the annuity's nominal total, so the pricing argument payers actually run is time-value and risk-adjusted, not sticker-price comparison. The CGTA annuity, not the WAC, is the real US SMA pricing precedent. Five questions this report answers: Q1 - How does the ten-state Medicaid CGTA annuity actually reprice Zolgensma versus its $2.125M WAC? Q2 - What does the Part B versus Part D benefit-routing split cost patients across nusinersen and risdiplam? Q3 - How does one-time gene therapy pricing compare to ten-year cumulative chronic-therapy cost? Q4 - What milestone criteria determine continuation of the CGTA annuity payment each year? Q5 - Which chronic therapy costs more in its loading year, nusinersen or risdiplam? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #SMA #SpinalMuscularAtrophy #Zolgensma #US #Medicaid #PricingStrategy Live report page: https://lnkd.in/dZPsr5i7

SPINAL MUSCULAR ATROPHY — UNITED KINGDOM NICE rejected Zolgensma in 2021, then reversed in 2023 by extending the QALY modelling horizon, not the discount. NICE rejected Zolgensma under its Highly Specialised Technologies route in 2021, when the cost per QALY at WAC, approximately £1.8 million, exceeded £200,000 without an adequate discount. Novartis did not simply cut price to win reversal. It returned in 2022 with a revised Patient Access Scheme, and NICE applied its Long-Term Value Framework, a methodology that extends cost-effectiveness modelling beyond the standard thirty-year horizon to reflect gene therapy's potentially durable effect. The 2023 decision accepted the case under a Managed Access Agreement requiring two years of real-world outcome data across six NHS gene therapy centres. The mechanism that flipped the decision was the modelling horizon, not the discount depth. Priced against that reversal, an estimated £1.2 to 1.6 million PAS net cost for a newborn-screening-identified infant beats an estimated £4.5 to 7.5 million lifetime cost of chronic therapy, nusinersen or risdiplam at roughly £150,000 to £250,000 a year over thirty-plus years. Nusinersen alone runs £150,000 to £250,000 a year in maintenance, with a £500,000 to £700,000 loading year, and combined NHS chronic SMA spend is estimated at £45 to £75 million annually. Any new UK entrant has to price against this exact break-even logic, since NICE will not reward parity pricing once an incumbent has already cleared the QALY bar. NICE will not reward parity pricing once an incumbent has cleared the QALY bar. Five questions this report answers: Q1 - How did NICE's Long-Term Value Framework, rather than a bigger discount, flip Zolgensma's 2021 rejection to 2023 acceptance? Q2 - What does the PAS net cost versus lifetime chronic-therapy cost imply for a new entrant's pricing strategy? Q3 - Why won't NICE reward parity pricing once nusinersen and risdiplam already clear the QALY bar? Q4 - What real-world data does the Managed Access Agreement require, and over what timeframe? Q5 - How much does NHS England spend annually on chronic SMA therapy across nusinersen and risdiplam? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #SMA #SpinalMuscularAtrophy #NICE #UK #Zolgensma #PricingStrategy Live report page: https://lnkd.in/dqA3QHpp

SPINAL MUSCULAR ATROPHY — GCC NPHC's Zolgensma discount looks like 15 to 20 percent, but a 24-month milestone rebate is the real mechanism. Novartis negotiated a GCC Zolgensma price of approximately $1.5 to 1.8 million one-time, against a $2.125 million US list, a 15 to 20 percent headline discount. But the discount is not what makes the price defensible to NPHC's budget committee. The structure is an outcomes-based milestone rebate: if a treated infant does not achieve independent sitting by 24 months, following the same logic as the CMS Cell and Gene Therapy Access precedent NPHC explicitly referenced, a rebate is triggered. That milestone-rebate architecture, not the percentage discount, is the actual mechanism, and it is now the template NPHC applies when evaluating any high-cost rare-disease therapy. Chronic therapy prices against the same logic from the other direction. Risdiplam runs an estimated SAR 700,000 to 800,000 a year, roughly 60 to 70 percent of US WAC after tender negotiation, while nusinersen costs SAR 350,000 to 400,000 per injection on a quarterly maintenance schedule, with first-year loading reaching SAR 1.4 to 1.6 million. Over a Type 2/3 patient's lifetime from diagnosis at age two through age thirty, cumulative risdiplam cost reaches an estimated SAR 20 to 25 million, a budget exposure large enough that NPHC's continuation-monitoring framework functions as its own form of outcomes-based pricing even without a formal rebate clause. A new entrant prices against both a milestone-rebate and a continuation-monitoring mechanism at once. Five questions this report answers: Q1 - What are the exact terms of NPHC's 24-month motor-milestone rebate for Zolgensma? Q2 - How does NPHC's continuation-monitoring framework function as its own outcomes-based pricing mechanism for chronic therapy? Q3 - What price should a new SMA entrant expect from NPHC, and which mechanism applies? Q4 - How much does cumulative risdiplam cost reach over a Type 2/3 patient's lifetime in the GCC? Q5 - Which CMS precedent did NPHC explicitly reference when structuring its Zolgensma milestone rebate? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #SMA #SpinalMuscularAtrophy #GCC #NPHC #Zolgensma #PricingStrategy Live report page: https://lnkd.in/drN7dvJq

SICKLE CELL DISEASE — US Casgevy and Lyfgenia list at $2.2M and $3.1M, but CMS's Cell and Gene Therapy Access Model decides the realized net price, not the sticker. The US sickle cell payer question stopped being whether Casgevy and Lyfgenia are covered and became what net price CMS's Cell and Gene Therapy Access Model actually produces once the roughly $2.2 million and $3.1 million list prices pass through a Medicaid-dominant population. Sixty to seventy percent of US SCD patients are Medicaid-insured, concentrated in Southern states, so the statutory 23.1 percent rebate plus negotiated supplemental rebates does most of the gross-to-net work before any state ever signs an outcomes contract. CGTA lets participating state Medicaid programs tie manufacturer payment to durable vaso-occlusive-crisis freedom, with a best-price rebate waiver so outcomes-linked payment does not trigger a punitive best-price recalculation across a manufacturer's book of business. ICER has already put a number on what it considers fair: a $1.5 to $1.9 million fair-value ceiling for Casgevy, public and citable in any payer negotiation. Below that ceiling sits a far cheaper, mandatory checkpoint. Every payer requires a documented hydroxyurea trial at maximum tolerated dose for at least six months, a roughly $600-a-year prerequisite, before authorizing either gene therapy. Because only 25 to 30 percent of eligible patients are even on hydroxyurea today, that step-edit adds real months to a pathway already running through qualified-center referral, apheresis, and myeloablative conditioning, while Lyfgenia's boxed warning for hematologic malignancy leaves most commercial plans preferring Casgevy within the class. Medicaid concentration and CMS's outcomes model, not list price, decide the realized net. Five questions this report answers: Q1 - How does CMS's Cell and Gene Therapy Access Model convert list price into a realized Medicaid net price? Q2 - What fair-value ceiling has ICER already set for Casgevy, and how should a pricing model position against it? Q3 - How do the hydroxyurea step-edit and Lyfgenia's boxed warning reshape the realized GTN waterfall? Q4 - What does the best-price rebate waiver protect in an outcomes-linked Medicaid contract? Q5 - Which payer channel or comparator class can a commissioned pricing model be scoped around? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #SickleCellDisease #GeneTherapy #Casgevy #Lyfgenia #PricingStrategy #Medicaid Live report page: https://lnkd.in/d8jx565r

SICKLE CELL DISEASE — UK NICE rejected crizanlizumab at £733K-1.1M per QALY even with a PAS discount, and Casgevy cleared only via a 10-year, £165K-a-year annuity. The defining UK sickle cell pricing precedent is not a success story. NICE reviewed crizanlizumab under TA743 in 2021 and did not recommend it for routine NHS commissioning, even after Novartis offered a confidential Patient Access Scheme discount. At a UK WAC of roughly £88,000 a year, the modelled cost came to £733,000 to £1.1 million per QALY, far outside NICE's standard threshold, and the drug was withdrawn from the market in 2023 after its confirmatory trial failed. Any new non-gene sickle cell agent inherits that precedent directly: a WAC anywhere near crizanlizumab's is very unlikely to clear NICE, whatever the clinical case. Casgevy's own path illustrates the same constraint at gene-therapy scale. Its £1.65 million one-time WAC compares favourably against an estimated £4-6 million NHS lifetime cost of managing a severe SCD patient, but a single lump-sum payment of that size was never going to clear an NHS budget line cleanly. NICE's TA1044 recommendation rests on a managed-access agreement, and NHS England's own modelling frames the economics as a 10-year annuity: roughly £165,000 a year per patient, a marginal improvement over the £80,000-£120,000 a year NHS already spends managing severe SCD conventionally. A new non-gene agent must price near £15,000-25,000 a year, not anchor to crizanlizumab's WAC. Five questions this report answers: Q1 - Why did NICE reject crizanlizumab even with a PAS discount, and what WAC range would have cleared it? Q2 - How does Casgevy's 10-year annuity model change the economics of a £1.65M one-time gene therapy? Q3 - What target WAC should a new non-gene SCD agent set, given the NHS hospitalisation-offset argument? Q4 - Why was crizanlizumab withdrawn from the market in 2023 after its confirmatory trial failed? Q5 - Can a specific WAC scenario or comparator set be modelled for a UK SCD launch? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #SickleCellDisease #UK #NICE #Crizanlizumab #Casgevy #PricingStrategy Live report page: https://lnkd.in/dwssSuzn

SICKLE CELL DISEASE — GCC At 200,000-250,000 GCC patients, NPHC's exceptional-access threshold caps a novel agent near SAR 8,000-20,000 a year. GCC sickle cell disease pricing runs on a mechanism most Western pricing models never encounter: population scale itself as the binding constraint. At an estimated 200,000 to 250,000 patients region-wide, with 140,000 to 200,000 in Saudi Arabia alone, NPHC's rare-disease exceptional-access threshold for conditions affecting more than 100,000 Saudi patients sits at SAR 10,000 to 30,000 a year, a small fraction of US pricing of $30,000 to $80,000 or UK pricing in the tens of thousands of pounds. A novel agent that prices to a US or UK comparator will simply not clear NPHC's budget line, regardless of clinical merit, because the population multiplying that price is an order of magnitude larger than in any Western market. Gene therapy illustrates the same discount at scale. Casgevy and Lyfgenia are expected to reach the GCC at an estimated $1.2 to $1.8 million once SFDA registration completes, a real discount against the $2.2 million US WAC, but administration will be confined to fewer than 10 GCC patients a year given HSCT-centre capacity and Islamic ethics-committee review of lentiviral and CRISPR vectors. The conventional-therapy market, priced against hydroxyurea's SAR 3,000 to 5,000 a year generic floor, is where population-scale economics actually bite. A novel agent reducing vaso-occlusive-crisis frequency by 30 to 50 percent generates an estimated SAR 36 to 187 million a year in NPHC hospitalisation savings. Population scale, not clinical merit, sets NPHC's exceptional-access pricing ceiling. Five questions this report answers: Q1 - Why does population scale, not clinical need, set NPHC's exceptional-access pricing threshold? Q2 - What GCC discount should gene therapy expect against its $2.2M US WAC, and how does HSCT capacity cap uptake? Q3 - How large is the VOC-reduction health-economics case, and how does NPHC weigh it against hydroxyurea's cost floor? Q4 - Why does gene therapy uptake stay confined to fewer than 10 GCC patients a year? Q5 - Which market basket or comparator set can a commissioned GCC pricing model target? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #SickleCellDisease #GCC #NPHC #GeneTherapy #PricingStrategy #Hydroxyurea Live report page: https://lnkd.in/d9zxSuN7

PSORIASIS — US Stelara's negotiated price falls to $4,695 from a $13,836 list, a 66% cut, effective January 2026, the same month ustekinumab biosimilars begin launching. Two separate pricing shocks land on one legacy biologic at once. IRA negotiation has already reset the legacy biologic tier in psoriasis. CMS's negotiated Maximum Fair Price for Stelara (ustekinumab), on a 30-day equivalent basis, is $4,695 against a $13,836 list, a 66% cut, effective January 1 2026. Enbrel (etanercept) is cut similarly: $2,355 negotiated against a $7,106 list, a 67% reduction, effective the same date. Both cuts land on agents that have already been on the market for years and carried established payer contracts built around list-minus-rebate economics; the negotiated price replaces that entire structure at once. The second shock lands on the same calendar. Nine to ten adalimumab biosimilars launched in 2023 and have already reshaped the TNF-inhibitor tier (Humira's own franchise). Ustekinumab biosimilars begin launching from January 2025, meaning Stelara faces biosimilar erosion in the same window as its IRA-negotiated price takes effect. A pricing strategy that models the IRA cut in isolation, without the biosimilar entry hitting the same product in the same period, will misprice the actual net-revenue trajectory; the two forces compound rather than offset. ICER's 2018 assessment gives the value-based ceiling this class has been measured against since before either shock: cost-per-QALY ranged from roughly $131,000 for brodalumab to $188,000 for certolizumab pegol across the biologic class, and ICER's report explicitly recommended that payers limit or abolish step therapy requirements for these agents. That step-therapy recommendation matters directly for pricing strategy: any negotiated-price or biosimilar-entry model has to account for whether payer utilization management is loosening or holding, since UM policy changes the effective volume each price point actually reaches. Stelara's negotiated price and its first biosimilar launch land in the same month. That collision, not either force alone, is the pricing event this model is built to quantify. 3 questions this report answers: Q1 - How do the IRA-negotiated prices for Stelara and Enbrel compare, and what does a 66-67% cut on both do to legacy-biologic contracting? Q2 - What happens when Stelara's IRA-negotiated price and the ustekinumab biosimilar wave hit in the same window, and how does that compound versus a single-shock model? Q3 - Where do ICER's 2018 cost-per-QALY benchmarks sit relative to the newly negotiated prices, and does ICER's step-therapy recommendation change the access equation? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #Psoriasis #US #PricingStrategy #AXLRx #PharmaMarketAccess Live report page: https://lnkd.in/dnZ8V9Sp

POMPE DISEASE — UNITED STATES Pombiliti plus Opfolda runs $600,000 to $800,000 a year, split across Medicare Part B and Part D. All three approved US Pompe enzyme replacement therapies are intravenous infusions billed under the Medicare Part B medical benefit, which removes patient out-of-pocket cost for most Medicare and Medicaid beneficiaries. Alglucosidase alfa carries an annual WAC near $400,000, and avalglucosidase alfa prices at roughly $400,000 to $450,000, a modest premium tied to its six-minute-walk advantage. The Pombiliti plus Opfolda regimen breaks this pattern: cipaglucosidase alfa infuses under Part B while its oral chaperone, miglustat, routes to Part D, creating a $600,000 to $800,000 combined annual cost and a two-benefit coordination burden that some plans are still not configured to process cleanly. Payers treat alglucosidase alfa as the step-edit incumbent regardless of trial data, and most commercial plans require six to twelve months of documented inadequate response before authorizing a next-generation switch. Pompe disease has never received a formal ICER cost-effectiveness review, unlike myasthenia gravis, SMA, or ATTR amyloidosis; a review is expected in 2025, and until it lands payers benchmark against Gaucher-disease ERT rather than a Pompe-specific QALY threshold. A new entrant should plan for a twelve-month HCPCS J-code lead time and expect its price ladder to be judged against the $400,000 to $800,000 band already established. No ICER review exists yet, so payers benchmark Pompe pricing against Gaucher disease. Five questions this report answers: Q1 - Why does the Pombiliti plus Opfolda regimen split across Medicare Part B and Part D? Q2 - What price ladder should a new Pompe ERT entrant target given the established $400,000-800,000 band? Q3 - How should a new entrant price against a therapy area with zero ICER reviews to date? Q4 - How long is the HCPCS J-code lead time a new Pompe ERT entrant should plan for? Q5 - Why do payers currently benchmark Pompe ERT pricing against Gaucher disease instead of a Pompe-specific threshold? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #PompeDisease #LOPD #US #RareDisease #PricingStrategy #Medicare Live report page: https://lnkd.in/dubzTX5T

POMPE DISEASE — UNITED KINGDOM NICE's TA821 recommendation lets avalglucosidase alfa carry a 20 to 30 percent premium, yet budget impact is just £2 to 4 million a year. Alglucosidase alfa has been commissioned by NHS England as a highly specialised service since 2014 under a clinical commissioning policy rather than a formal NICE technology appraisal. A confidential Patient Access Scheme brings net cost to an estimated £200,000 to £350,000 per patient per year for the roughly 180 UK patients currently on ERT. Avalglucosidase alfa has since cleared NICE under TA821, with its own confidential commercial arrangement, carrying an estimated 20 to 30 percent WAC premium over alglucosidase. The defined switch-eligible population, roughly 45 to 50 patients showing FVC decline despite alglucosidase, keeps the incremental NHS budget impact to a manageable £2 to 4 million a year. The harder number sits behind the TA821 recommendation, not in front of it. The pre-PAS cost-effectiveness case for avalglucosidase's incremental FVC and six-minute-walk improvement over alglucosidase runs an estimated £1 to 4 million per QALY, a genuinely difficult profile that only cleared NICE's threshold after deep confidential discounting. A stronger case exists in the ventilator-avoidance argument: each year of mechanical-ventilation dependency avoided carries an estimated 0.36 QALY gain, a materially larger utility case than incremental walk-distance improvement. Any new entrant's pricing strategy should build around ventilator avoidance rather than compete on the same comparator. Broader first-line uptake, not the defined switch population, would be the larger budget event. Five questions this report answers: Q1 - What does NICE's TA821 recommendation reveal about the pricing a new Pompe agent will need to clear? Q2 - Why is the switch-population budget impact manageable while broader first-line uptake would not be? Q3 - Is there a stronger NICE case than competing on incremental FVC or six-minute-walk improvement? Q4 - What net cost does NHS England pay for alglucosidase alfa after its confidential Patient Access Scheme? Q5 - How large is the ventilator-avoidance QALY gain that could anchor a new agent's NICE case? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #PompeDisease #NICE #UK #NHS #PricingStrategy #RareDisease Live report page: https://lnkd.in/dbTZNRyW